Amgen Inc (AMGN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $251.89B
Last updated: Nov 17, 2026 at 11:05 AM ET
Amgen Inc (AMGN) P/E Ratio & Valuation History
Amgen (AMGN) trades at 19.9x trailing earnings and 6.4x sales. Its P/E of 19.9x is above its 5-year median of 14.7x. Its forward P/E is 19.1x. The median P/E across 9 similar companies is 21.4x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 4.2% higher over the next year. Its free cash flow yield is 3.8%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 19.9x |
| Forward P/E | 19.1x |
| Price to sales | 6.4x |
| Price to book | 17.4x |
| EV/EBITDA | 16.0x |
| Price to FCF | 26.1x |
| EV/FCF | 30.4x |
| PEG | 2.8 |
| FCF yield | 3.8% |
Historical Medians
Against its 10-year medians, its P/E is 39.2% above 14.3x, its P/S is 20.8% above 5.3x and its P/B is 10.1% above 15.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 19.9x | 14.7x | 14.3x |
| P/S | 6.4x | 5.1x | 5.3x |
| P/B | 17.4x | 23.4x | 15.8x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 12.6x in 2016 to 16.3x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $327.31 | 15.0x | 4.8x | 20.5x |
| 2024 | $260.64 | 13.2x | 4.2x | 24.0x |
| 2023 | $288.02 | 15.4x | 5.5x | 25.0x |
| 2022 | $262.64 | 14.8x | 5.4x | 38.7x |
| 2021 | $224.97 | 13.1x | 4.9x | 19.0x |
| 2020 | $229.92 | 13.9x | 5.3x | 14.3x |
| 2019 | $241.07 | 16.3x | 6.3x | 14.9x |
| 2018 | $194.67 | 13.5x | 5.4x | 10.0x |
| 2017 | $173.90 | 13.8x | 5.6x | 5.0x |
| 2016 | $146.21 | 12.6x | 4.8x | 3.7x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About AMGN
What is AMGN's forward P/E ratio?
Amgen has a forward P/E ratio of 19.1x.
Is AMGN stock overvalued?
GNG's valuation label for AMGN is Overvalued. Its P/E of 19.9x compares with a median of 21.4x across 9 similar companies.
What is AMGN's price to sales ratio?
Amgen has a price to sales ratio of 6.4x.
What is Amgen's average P/E ratio over 5 years?
Amgen's median P/E over the last 5 years is 14.7x, from 60 month-end values through Oct 2026.
What is AMGN's PEG ratio?
Amgen has a PEG ratio of 2.8.
AMGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts